실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

8,428+프로그램
40+FDA 승인
3,743+모집 중
ADC 1032·Antibody 4683·CGT 2713차세대 추천 →·Data Tier →
8428프로그램40FDA 승인
27오늘 방문
1,480누적 방문
7303갱신 대기S–CData TierS/A/B차세대→Insight1032HER2 breast4683Antibody2713CGT→Psoriasis→NSCLC40FDA 승인
피드Data Tier차세대Insight

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · EbglyssPCSK9 · LDLRepatha · Praluent · LeqvioGLP-1 · incretinSemaglutide · Tirzepatide혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

최근 활동

RSS →

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
다음 갱신 D-13 · 마지막 7월 21일
AntibodystaleEli LillyPhase 2

cisplatin, vinorlebine, cetuximab (cisplatin, vinorlebine, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

cisplatine, etoposide, cetuximab (cisplatine, etoposide, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 1

pCAR-19B cells (pCAR-19B cells)

Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 1

Peri operative Cetuximab. (Peri operative Cetuximab.)

Colon Cancer · Colon Cancer

#ColonCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleEli LillyPhase 1

Nilotinib + Cetuximab (Nilotinib + Cetuximab)

Colorectal Cancer; Head and Neck Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleEli LillyPhase 2

gemcitabine + cetuximab (gemcitabine + cetuximab)

Time to Progression · Time to Progression

#TimetoProgression#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJiangsu HengruiPhase 3

Camrelizumab and Chemotherapy (Camrelizumab and Chemotherapy)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

Adebrelimab + Cetuximab+ Chemotherapy (Adebrelimab + Cetuximab+ Chemotherapy)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 1

Brivanib + Cetuximab (Brivanib + Cetuximab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJiangsu HengruiPhase 3

Camrelizumab and Cetuximab (Camrelizumab and Cetuximab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

Tunlametinib + Cetuximab β (Tunlametinib + Cetuximab β)

Lung Cancer (NSCLC) · Lung Cancer (NSCLC)

#LungCancerNSCLC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

Everolimus, Cetuximab, Irinotecan (Everolimus, Cetuximab, Irinotecan)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleEli LillyPhase 2

Oxaliplatin, capecitabine, gemcitabine, cetuximab (Oxaliplatin, capecitabine, gemcitabine, cetuximab)

Cholangiocarcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleWest China HospitalPhase 2

Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors (Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors)

Cancer of Biliary Duct · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
CGTBiologicstaleMarino Biotechnology Co., Ltd.Phase 1

autologous anti-CD19 CAR T cells (autologous anti-CD19 CAR T cells)

B-cell Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

Encorafenib Oral Capsule + Cetuximab (Encorafenib Oral Capsule + Cetuximab)

Colorectal Cancer; BRAF V600E Mutation Positive · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 3

Experimental: mXELOX plus cetuximab (Experimental: mXELOX plus cetuximab)

Colo-rectal Cancer · Colo-rectal Cancer

#Colo-rectalCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Altuzan (Subconjunctival bevacizumab, Subconjunctival bevacizumab (Altuzan))

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
ADCBiologicstaleRochePhase 2

Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy (Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
AntibodystaleSanofiPhase 1

dupilumab (DUPIXENT®, DUPIXENT® (dupilumab))

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
CGTBiologicRoswell Park Cancer InstitutePhase 1

Autologous Anti-CD83 CAR T-cells (Autologous Anti-CD83 CAR T-cells)

Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystaleSanofiPreclinical

Systemic dupilumab (Systemic dupilumab)

Dermatitis, Atopic · Dermatitis, Atopic

#DermatitisAtopic#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, 89Zr-Pembrolizumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
ADCBiologicstaleJiangsu HengruiPhase 2

A2: SHR-A1811 with Camrelizumab with famitinib (A2: SHR-A1811 with Camrelizumab with famitinib)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstaleCancer Research UKPhase 1

1RG-CART (1RG-CART)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE

133 / 142 페이지

← 이전다음 →
전체 8,428개 프로그램 보기